Insulin pills may soon replace daily injections
Why it matters: This breakthrough could eliminate daily insulin injections, drastically improving quality of life for millions with diabetes.
- Kumamoto University has developed a novel approach using a cyclic DNP peptide to enable oral insulin delivery, overcoming the long-standing challenge of digestive breakdown.
- The research team, led by Associate Professor Shingo Ito, demonstrated two effective strategies—a mixing method and a conjugation method—both successfully lowering blood sugar in diabetes models.
- This new platform significantly reduces the required insulin dose, achieving a high pharmacological bioavailability of 33-41%, making oral insulin far more practical for real-world use compared to previous attempts requiring ten times higher doses.
- Associate Professor Shingo Ito believes this peptide-based platform could also be applicable to long-acting insulin formulations and other injectable biologics, expanding its future potential beyond current diabetes treatments.
For over a century, the "dream" of oral insulin has been thwarted by the digestive system, forcing millions of diabetes patients to rely on daily injections. Now, Kumamoto University researchers have developed a groundbreaking peptide-based platform that allows insulin to be absorbed through the intestinal wall, potentially replacing daily injections with a pill.
